Shots: Icagen to receive upfront, up to $274M milestones and royalties on sales from Roche and is responsible for all preclinical activities Roche to fund the program and will perform […]readmore
Tags : Development
Shots: Beigene to get exclusive development and commercialization rights to ZW’s ZW25 and ZW49 candidates in Asia, New Zealand and Australia (ex. Japan). ZW to receive $40M upfront, $390M milestones […]readmore
Shots: The companies will jointly develop vaccine candidates using Leidos’ PD-1 checkpoint inhibitors combined with GeoVax’s MVA-VLP vaccine platform GeoVax will design, construct, and characterize the developed product and further […]readmore
Shots: Henry to get an exclusive option to license US patent application 14/654,140 for Galectin-3 inhibitors and will acquire minority equity in G3 Pharmaceuticals The focus of the agreement is […]readmore
Shots: Halozyme to receive $25M upfront plus $160 to $165M/target milestones payments based on development, regulatory & sales in addition to royalties. Roche to get rights for ENHANZE Technology for […]readmore
Shots: Palette to receive global development rights for Nestle’s Deflux, Solesta and Barrigel and will focus on its commercialization. Nestle will continue to develop the license products for Palette The […]readmore
Shots: The termination of 2014 deal with Samsung, is the result of Lusduna Nexvue’s sales and production costs. Samsung receives $155M as total termination cost including investment and interest on […]readmore
Shots: The agreement is focus on developing and commercializing ARO-HBV that can improve QoL for chronic hepatitis B It includes drug candidate ARO-HBV along with option to license three additional […]readmore
Shots: Dragonfly Therapeutics will receive an upfront $695M with milestone and royalties on sales and Merck to get option to license exclusive worldwide IPR rights of products developed using Dragonfly’s […]readmore
Shots: The agreement is focused on development of needle-free and solid-dose formulation for Shigella flexneri 2a artificial Invaplex (Sfl2a InvaplexAR) vaccine using Enesi Pharma’s ImplaVax technology WRAIR will examine biochemical […]readmore